Company: DHR
Filing Date: 2025-03-26
Form Type: ARS
Source: 0000313616-25-000085
Chunk: 3

Company: DANAHER CORP /DE/
Filing Date: 2025-03-26
Form: ARS
Chunk 3
---
 us to strategically pursue high-value opportunities that can drive sustainable growth and long-term shareholder value. Breakthroughs in science and medicine are rarely achieved in isolation. Through our Beacons program, we invest in pioneering academic research with the goal of developing and commercializing transformative technologies and applications that can shape the future of healthcare. In 2024, we launched a groundbreaking collaboration with Nobel laureate Jennifer Doudna and the Innovative Genomics Institute (IGI) to advance gene-editing therapies for rare and complex diseases. By bringing together leading scientific minds and cutting-edge technology, the Danaher-IGI Beacon for CRISPR Cures is aiming to set a new standard for how genomic medicines are developed—bringing the promise of these therapies closer to reality. Innovation is at the heart of everything we do. These examples showcase how our innovation engine is driving Danaher’s long-term growth while enabling faster, more accurate diagnoses and reducing the time and cost of developing life-saving therapies. Building the Best Team Our people are the driving force behind our strategy, and we are committed to recruiting, developing, and retaining top talent to ensure we continue delivering meaningful impact. That’s why “The Best Team Wins” is the first of our five Core Values. This year, we were pleased to elevate Julie Sawyer Montgomery to Executive Vice President of our Diagnostics segment. Over the past eight years, Julie’s leadership has been instrumental in driving growth and enhanced performance at Beckman Coulter Diagnostics and across our Diagnostics businesses. With a deep commitment to customers, team-building, and DBS-driven innovation, Julie has made a lasting impact, and we look forward to her continued leadership in advancing our Diagnostics offerings to improve patient outcomes.

“ I firmly believe that when we bring together the passion and dedication of our teams, the scope and scale of our innovations, and our deeply ingrained commitment to continuous improvement, the potential for both long-term value creation and positive impact is limitless.” A Future Full of Potential We believe Danaher is better positioned than at any point in our 40-year history. The transformation in our portfolio over the last five years has shaped us into a focused life sciences and diagnostics innovator, with improved revenue growth, margin, and cash flow profiles. While our 2024 results did not fully demonstrate the power of our portfolio given challenging end-market conditions, a steadily improving operating environment—paired with our team’s commitment to leading with the Danaher Business System—reinforces our confidence in the bright future ahead for Danaher. Looking